Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BA3151
- Development stage
- Preclinical
- Lead developer
- BioAtla
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BA3151 is a second-generation antibody-drug conjugate (ADC) developed by BioAtla, Inc., targeting B7-H4 (also known as VTCN1). It utilizes BioAtla's proprietary Conditionally Active Biologics (CAB) platform, which is designed to ensure that the antibody binds to its target specifically within the unique microenvironment of diseased tissue, such as the acidic conditions typical of tumors, while remaining inactive in healthy tissues. This approach aims to enhance the therapeutic index by reducing off-target toxicities. BA3151 is intended for the treatment of various solid tumors, including breast, colon, kidney, ovarian, and prostate cancers, where B7-H4 is often overexpressed and associated with poor clinical outcomes. The drug is currently in the preclinical stage of development.
- Other names
- CAB-B7-H4-ADCCAB-B-7-H4-ADCCAB-B 7-H4-ADC
02
Targets
VTCN1 (V-set domain containing T cell activation inhibitor 1)
Beyond the preview
Go deeper on BA3151.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BA3151.